Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 95
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 11 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Tirzepatide improves HbA1c and body weight in Korean adults with T2D
Last updated July 18, 2026
Key finding
HbA1c was reduced from baseline by 2.75% to 3.25%.
This study evaluated the efficacy and safety of tirzepatide in Korean patients with type 2 diabetes, showing significant reductions in HbA1c and body weight.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy and safety of tirzepatide in Korean patients with type 2 diabetes, showing significant reductions in HbA1c and body weight.
Clinical relevance
These findings are clinically significant as they suggest that tirzepatide could be an effective treatment option for managing type 2 diabetes in Korean patients, potentially leading to better long-term health outcomes and reduced complications associated with diabetes.
Keep in mind
The study's design was a post hoc analysis, which may limit the strength of conclusions. Sample size and demographic specifics may affect generalizability to broader populations. Potential unmeasured confounders could influence the outcomes.
Published in
Journal Reference
Publication details and source links for this paper.
Byung WL, Chang BL, Soo L, et al. Post hoc analysis of tirzepatide efficacy and safety in Korean patients with type 2 diabetes. Diabetes, Obesity & Metabolism. 2025;27(12):7110-7122. doi:10.1111/dom.70111
Main Effects
HbA1c was reduced from baseline by 2.75% to 3.25%.
LSM body weight reductions of -6.8% to -10.9% from baseline were achieved.
HbA1c targets of <7.0% and ≤6.5% were achieved by 84.6% to 100% at week 52.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide and Body weight, Composite endpoint achievement, HbA1c, and 1 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
- Body weight
- Composite endpoint achievement
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
4
Evidence pairs
546
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and HbA1c
Related evidence
Evidence relationship
GLP-1 Receptor Agonists and Body Weight
Save evidence
Evidence topic
HbA1c Reduction
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Composite endpoint achievement
Tirzepatide → Composite endpoint achievement
Tirzepatide → Composite endpoint achievement
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 96
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 12 studies
Add to Evidence TrackerProportion achieving HbA1c <7.0%
Tirzepatide → Proportion achieving HbA1c <7.0%
Tirzepatide → Proportion achieving HbA1c <7.0%
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- HbA1c decreased by 2.75% to 3.25%, indicating effective blood sugar control.
- Body weight decreased by 6.8% to 10.9%, showing significant weight loss.
- Up to 100% of participants achieved HbA1c targets at week 52.
Who this applies to
- Korean patients diagnosed with type 2 diabetes.
- Adults aged 18 and older with inadequate glycemic control.
Keep in Mind
- Results are based on a specific population and may not apply to all ethnic groups.
- The study's observational nature may introduce biases.
- Further research is needed to confirm long-term efficacy and safety.
Between the Lines
- The study's design was a post hoc analysis, which may limit the strength of conclusions.
- Sample size and demographic specifics may affect generalizability to broader populations.
- Potential unmeasured confounders could influence the outcomes.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 96
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 12 studies
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 95
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 11 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
12 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
12 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
11 studies
outcome_hubMeasures Body Weight as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Tirzepatide and HbA1c
Intervention: TirzepatideOutcome: HbA1c
12 results
All studies on Tirzepatide and Body weight
Intervention: TirzepatideOutcome: Body weight
11 results
All studies on Tirzepatide
Intervention: Tirzepatide
12 results
All studies measuring HbA1c
Outcome: HbA1c
12 results
All studies measuring Body weight
Outcome: Body weight
11 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 83.9 | strong positive | ConsistencyScore™ Consistent | 1 study
- 2
Proportion achieving HbA1c <7.0%
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 29 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 83.3 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Tirzepatide improve composite endpoint achievement?
Emerging Evidence
Current evidence does not show a clear benefit of Tirzepatide for Composite endpoint achievement.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Composite endpoint achievement
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Tirzepatide improves glycemic control in early-onset type 2 diabetesTirzepatide improves cardiometabolic health in obesity.Tirzepatide enhances insulin sensitivity in type 2 diabetesDietary interventions improve glycemic control in pre-diabetic patientsOnce-weekly semaglutide improves glycemic control in Korean adults with T2D
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.